Phase 4 N=34 Estrogen Variability and Irritability During the Menopause Transition
Menopause · Irritable Mood
Primary: Mean IDAS Ill Temper Scale Score Over Time — 6.19; 6.02 score on a scale — p=0.09
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=107 A Randomized Control Trial Assessing the Effect of Topical Tranexamic Acid on Risk of Hematoma in Breast Surgery
Hematoma Postoperative
Primary: Hematomas — 0; 1 hematomas — p=0.486
Phase 4 N=36 MIcrovascular dysfuNction In Moderate-severe Psoriasis
Psoriasis · Cardiovascular Disease
Primary: Change in Global Coronary Flow Reserve (CFR) After 6 Months of Therapy With Tildrakizumab — -0.03 CFR Ratio
Phase 4 N=20 INF108F in Infants With Food Protein Induced Proctocolitis
Infant Development · Gut Microbiome · Food Protein Induced Allergic Proctocolitis
Primary: Changes to Gut Microbiome Composition — 42.816; -12.413 Change in %B.infantis reads (Day 28-BL) — p=0.154
Phase 4 N=9 A Study of Serum Folate Levels in Patients Treated With Olaparib
Ovarian Cancer · Breast Cancer · Folic Acid Deficiency
Primary: Number of Participants Who Have Developed Folate Deficiency (Serum Folate Level < 7 ng/ml) on Olaparib — 2; 6 Participants
Phase 4 N=20 Home Based Daratumumab Administration for Patients With Multiple Myeloma
Plasma Cell Myeloma
Primary: Treatment Satisfaction Will be Measured Using the SWT Score From the Cancer Treatment Satisfaction Questionnaire (CTSQ) - Cycle 1 — 87.2 scores on a scale (0-100)
Phase 4 N=1,188 The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
COVID-19 · Vaccine-Preventable Diseases · SARS CoV 2 Infection
Primary: Number of Symptomatic SARS-CoV-2 Infections Between Randomized, Study-vaccinated Participants and the Comparator Group — 48; 94 Participants
Phase 4 N=80 Outcomes of Once-Daily ICS/LABA/LAMA + PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations
Copd
Primary: Number of PRN Respiratory Therapy Drugs Per Day (PRN Treatments With Short Acting Bronchodilators Via Nebulization Given by Respiratory Therapists). — 0.03 treatments…
Phase 4 N=20 Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding
Hypofibrinogenemia · Bleeding
Primary: Total Number of RBCs Used Over Admission — 5.8; 6.7 RBC Units
Phase 4 N=13 ED-Initiated School-based Asthma Medication Supervision
Asthma · Asthma in Children
Primary: 90-day Emergency Department (ED) Recidivism — 1; 2 Participants
Phase 4 N=786 Optimizing Outpatient Anesthesia (OSPREy-Outpatient Surgery Pain Relief Enhancement)
Opioid Use · Pain, Postoperative
Primary: Total 30 Day Post-discharge Home Opioid Use (Number of Tablets) — 10.00; 10.00; 6.18; 6.67 tablets — p=0.970
Phase 4 N=17 Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis
Atopic Dermatitis · Atopic Dermatitis Eczema · Eczema
Primary: Percent Change in CD4+ T Effector Cells Expressing IL4 in Dupilumab-treated Subjects at Week 12 vs Week 0 — 68.4; 100.0 Percent change
Phase 4 N=51 Continuous Versus Cyclical OCP Use in PCOS
Polycystic Ovary Syndrome
Primary: Change in Biochemical Hyperandrogenism From Baseline to 1 Month Post Yasmin Initiation — -15.38; -8.54 ng/dl
Phase 4 N=72 Intrathecal Morphine for Cesarean Delivery
Postoperative Pain
Primary: Duration of Pain Relief — 24.5; 29.4; 32 hours
Phase 4 N=80 Nebulized Sub-dissociative Dose Ketamine at Three Different Dosing Regimens for Treating Acute Pain in the Pediatric ED
Pain
Primary: Pain Score Reduction From Baseline — 3.5; 3.2; 3.7 pain score